Nathan Rice
Stock Analyst at Piper Sandler
(4.36)
# 386
Out of 4,667 analysts
49
Total ratings
60%
Success rate
16.5%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $41.37 | +13.61% | 3 | Nov 1, 2024 | |
| MBIN Merchants Bancorp | Reiterates: Overweight | $56 → $48 | $38.19 | +25.69% | 5 | Oct 30, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $30.93 | +9.93% | 8 | Oct 29, 2024 | |
| BFC Bank First | Maintains: Neutral | $99 → $104 | $102.75 | +1.22% | 5 | Oct 17, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $56.83 | +30.21% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $109.48 | -23.27% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $223.87 | -12.00% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $13.44 | -33.04% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $418.61 | +3.92% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $323.39 | -27.95% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $59.10 | +40.44% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $18.38 | -18.39% | 1 | Dec 19, 2019 |
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $41.37
Upside: +13.61%
Merchants Bancorp
Oct 30, 2024
Reiterates: Overweight
Price Target: $56 → $48
Current: $38.19
Upside: +25.69%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $30.93
Upside: +9.93%
Bank First
Oct 17, 2024
Maintains: Neutral
Price Target: $99 → $104
Current: $102.75
Upside: +1.22%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $56.83
Upside: +30.21%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $109.48
Upside: -23.27%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $223.87
Upside: -12.00%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $13.44
Upside: -33.04%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $418.61
Upside: +3.92%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $323.39
Upside: -27.95%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $59.10
Upside: +40.44%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $18.38
Upside: -18.39%